S
Savara Inc. (SVRA)
NMS – Real Time Price. Currency in USD
5.08
-0.04 (-0.78%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
5.08
-0.04 (-0.78%)
At close: May 12, 2026, 4:00 PM EDT
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
| Name | Position |
|---|---|
| Brian Maurer | Head of Clinical Operations |
| Dr. Brian Robinson M.D. | Executive Vice President of Global Medical Affairs |
| Dr. Siddharth J. Advant Ph.D. | Executive Vice President of Global Technical Operations |
| Dr. Yasmine Wasfi M.D., Ph.D. | Chief Medical Officer |
| Mr. Charles LaPree | Executive VP & Head of Global Regulatory Affairs |
| Mr. David L. Lowrance CPA | Chief Financial & Administrative Officer and Secretary |
| Mr. Matthew Pauls J.D., M.B.A. | Chairman & CEO |
| Mr. Robert Matthew Lutz M.B.A. | Chief Operating Officer |
| Ms. Anne Erickson | Chief Business & Corporate Affairs Officer |
| Ms. Kate McCabe J.D. | Chief Legal Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-24 | DEFA14A | d12714ddefa14a.htm |
| 2026-04-24 | ARS | d57226dars.pdf |
| 2026-04-10 | PRE 14A | d11872dpre14a.htm |
| 2026-03-13 | 8-K | d107834d8k.htm |
| 2026-01-27 | 8-K | d39349d8k.htm |
| 2026-01-09 | 8-K | d24211d8k.htm |
| 2025-11-12 | 10-Q | svra-20250930.htm |
| 2025-09-02 | 8-K | d12513d8k.htm |
| 2025-08-13 | 10-Q | svra-20250630.htm |
| 2025-06-06 | 8-K | d58104d8k.htm |